儿童急性淋巴细胞白血病首次复发后生存的决定因素:儿童肿瘤协作组研究
该研究分析了1996至2014年纳入12项儿童肿瘤协作组一线ALL试验的16115例患者,其中2053例(12.7%)复发。复发后5年总生存率全队列为48.9±1.2%,B-ALL为52.5±1.3%,T-ALL为35.5±3.3%,婴儿ALL为21.5±3.9%。研究识别了与复发后总生存相关的预后因素,包括复发时间、遗传学亚型及复发部位。
要点
- 复发后5年OS全队列48.9±1.2%,B-ALL 52.5±1.3%,T-ALL 35.5±3.3%,婴儿ALL 21.5±3.9%。
- B-ALL复发后OS随复发时间延迟而升高:早期25.8±2.4%、中间49.5±2.2%、晚期66.4±1.8%。
- ETV6::RUNX1或+4+10者复发后OS较高(74.4±3.1%、70.2±3.6%),亚二倍体、KMT2A重排、TCF3::PBX1者OS较差。
核心结论
- 该大型数据集识别了儿童ALL首次复发后总生存的相关风险因素,以指导试验设计并突出复发后结局极差的群体。
研究设计与样本
- 分析1996至2014年纳入12项儿童肿瘤协作组一线ALL试验的16115例患者,其中2053例(12.7%)复发。
主要发现
- 复发率B-ALL为12.5%,T-ALL为11.2%,婴儿为34.2%。
- B-ALL约50%为晚期复发(≥36个月),72.5%累及骨髓;T-ALL 64.8%为早期复发(<18个月),47.1%累及中枢神经系统。
- 复发后5年OS全队列为48.9±1.2%,B-ALL为52.5±1.3%,T-ALL为35.5±3.3%,婴儿ALL为21.5±3.9%。
- B-ALL复发后OS按早期、中间、晚期分别为25.8±2.4%、49.5±2.2%、66.4±1.8%;T-ALL分别为29.8±3.9%、33.3±7.6%、58±9.8%。
- ETV6::RUNX1或+4+10者中位复发时间43个月,复发后OS分别为74.4±3.1%和70.2±3.6%;亚二倍体、KMT2A重排、TCF3::PBX1者中位复发时间12.5-18个月,复发后OS分别为14.2±6.1%、31.9±7.7%、36.8±6.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Limited prognostic factors have been associated with overall survival (OS) post-relapse in childhood Acute Lymphoblastic Leukemia (ALL). Patients enrolled on 12 Children's Oncology Group frontline ALL trials (1996-2014) were analyzed to assess for additional prognostic factors associated with OS post-relapse. Among 16,115 patients, 2053 (12.7%) relapsed. Relapse rates were similar for B-ALL (12.5%) and T-ALL (11.2%) while higher for infants (34.2%). Approximately 50% of B-ALL relapses occurred late (≥36 months) and 72.5% involved the marrow. Conversely, 64.8% of T-ALL relapses occurred early (<18 months) and 47.1% involved the central nervous system. The 5-year OS post-relapse for the entire cohort was 48.9 ± 1.2%; B-ALL:52.5 ± 1.3%, T-ALL:35.5 ± 3.3%, and infant ALL:21.5 ± 3.9%. OS varied by early, intermediate and late time-to-relapse; 25.8 ± 2.4%, 49.5 ± 2.2%, and 66.4 ± 1.8% respectively for B-ALL and 29.8 ± 3.9%, 33.3 ± 7.6%, 58 ± 9.8% for T-ALL. Patients with ETV6::RUNX1 or Trisomy 4 + 10 had median time-to-relapse of 43 months and higher OS post-relapse 74.4 ± 3.1% and 70.2 ± 3.6%, respectively. Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short median time-to-relapse (12.5-18 months) and poor OS post-relapse (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%). Site-of-relapse varied by cytogenetic subtype. This large dataset provided the opportunity to identify risk factors for OS post-relapse to inform trial design and highlight populations with dismal outcomes post-relapse.
引用
- Rheingold SR, Bhojwani D, Ji L, et al. Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2024. PMID: 39261601. doi:10.1038/s41375-024-02395-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。